Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD19‐directed immunotherapy use in KMT2A‐rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switch

3 Sept 2022

Abstract excerpt

To the Editor: Acute lymphoblastic leukemia (ALL) bearing the KMT2A-rearrangement is a high-risk genomic subgroup, characterized by chemotherapy-resistance and a propensity for rapid relapse with reported 5-year overall survival of less than 20%.1 Unique in its involvement in early leukemogenesis, KMT2A gene rearrangement has been described to confer overlapping immunophenotypic features of both myeloblasts and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36057135
DOI: 10.1002/ajh.26713

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD19‐directed immunotherapy use in KMT2A‐rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switchPMID 36057135Read ↗

CRLF2 -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapySemantic proximity Read ↗

Genetics and pathologic landscape of lineage switch of acute leukemia during therapySemantic proximity Read ↗

Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomabSemantic proximity Read ↗

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysisSemantic proximity Read ↗

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceSemantic proximity Read ↗

Genetics and Pathologic Landscape of Lineage Switch of Acute Leukemia during Therapy: A Multi-institutional StudySemantic proximity Read ↗

Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapySemantic proximity Read ↗

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A ( MLL ) rearrangement in adults: A single‐institution experienceSemantic proximity Read ↗

The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patientsSemantic proximity Read ↗

Phenotypic and genotypic infidelity in B-lineage neoplasms, including transdifferentiation following targeted therapy: Report from the 2021 SH/EAHP Workshop.Semantic proximity Read ↗

To B‐ or not to B‐: A review of lineage switched acute leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.